The Synergetic Effect of L-Prf® & The Ossean® Implant Surface

Robert J Miller1*, Marco Del Corso2 and Andrea Mascolo3

1Chairman Department of Oral Implantology, Atlantic Coast Dental Research Clinic, USA
2Private Practice, Turin, Italy
3D.D.S. MSc. (Oral Surg.) Associate Professor UFP University Fernando Pessoa, Portugal

Submission: October 02, 2017; Published: October 16, 2017

*Corresponding author: Robert J Miller DDS, FACD;DABOI, USA, Email: drrjmiller1@msn.com

Clinical outcomes in implant dentistry are dependent on a host of factors that are well documented. The evolution of our discipline has involved the physical manipulation of the site and materials used but now also includes the shaping of the biologic response. Speed of healing and the quality of the tissue regenerated are now considered two of the most important attributes as it relates to surgical success. As clinical outcomes are dependent on the types of biomaterials used, one of the strategies that we now employ is using the synergistic effect of a combination of these materials to ensure the best clinical outcomes. Our capacity to shorten treatment time for patients and still achieve successful function and aesthetics requires compression of the wound response.

Starting 20 years ago, the initial use of autologous growth factors, in the form of platelet rich plasma (PRP), enabled us to speed up the regeneration of soft tissue. As it had very little effect on hard tissue, researchers developed recombinant human growth factors in the form of platelet derived growth factor (rhPDGF) and bone morphogenetic protein (rhBMP) to address this inadequacy. While there was success in speeding up the process of regenerating hard tissue, the bone was relatively immature unless the clinician waited longer before placing implants. A decade ago, a second-generation autologous material in the form of leucocyte containing platelet rich plasma (L-PRF®) became available. The entire range of growth factors necessary for regeneration of both hard and soft tissue, in concentrated form, now enables us to predictably compress the wound response in ways we could not have imagined just a few years ago.

Recently published advances in these two individual biotechnologies lead a group of scientists to investigate just such a scenario. They reasoned that if an implant with an osteoinductive, bioactive surface (OSSEAN®) was immersed into a super blood clot (L-PRF®) obtained with the Intraspin™ system, bone should naturally grow in an extraction site defect between the bone and implant surface, even in the absence of initial stability. By simultaneously activating the bony socket and implant surface, this effect was confirmed in terms of treatment outcomes [3], what are the immediate and long-term synergistic effects of Intraspinal-PRF® and the OSSEAN® implant surface mean? More predictable results with fewer complications, faster healing and the ability to load the implants sooner. In the long-term, the bond that is formed between the implant and bone is stronger and able to better withstand functional forces. All very positive and profound outcomes for clinicians (Figure 1-4).
Figure 1: Without OSSEAN® and Without L-PRF® yielded poor bone formation and no osseointegration.

Figure 2: With OSSEAN® and without L-PRF® yielded increased bone formation in the gap area.

Figure 3: Without OSSEAN® and with L-PRF® yielded increased bone formation on the implant surface.

Figure 4: With OSSEAN® and with L-PRF® yielded greatest bone density and fastest degree of osseointegration.

References